SRRK

Scholar Rock Holding Corp

A biopharmaceutical company in Cambridge, Massachusetts that develops antibody medicines for muscle-wasting diseases. Its lead therapy, apitegromab, targets a protein that limits muscle growth and is being tested for spinal muscular atrophy. Founded in 2012 by Harvard Medical School researchers, the company takes its name from Chinese "scholar's rocks"—eroded stones prized for sparking insight—because their rugged shapes resemble the protein structures it studies.